Dataset Information


Increased expression of Ankyrin repeat domain 1 (ANKRD1) associates with the resistance mechanism of osimertinib resistant non-small cell lung cancer

ABSTRACT: EGFR tyrosine kinase inhibitors (EGFR-TKIs) induce a dramastic response in non-small cell lung cancer (NSCLC) patients with the EGFR mutation.However, acquired resistance to EGFR-TKIs in lung cancer cells Overall design: We established EGFR-TKI-resistant cells (PC-9-afatinib;PC-9-AR, PC-9-osimertinib; PC-9-OR, HCC827-afatinib; HCC827-AR, HCC827-osimertinib; HCC827-OR) to discover a novel mechanism of acquired resistance to EGFR-TKIs and a strategy to conquer EGFR mutation-positive lung cancer.

INSTRUMENT(S): [HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array [transcript (gene) version]

SUBMITTER: Akiko Takahashi  

PROVIDER: GSE106765 | GEO | 2017-11-11



Dataset's files

Action DRS
GSE106765_RAW.tar Raw
filelist.txt Txt
Items per page:
1 - 2 of 2
altmetric image


Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.

Takahashi Akiko A   Seike Masahiro M   Chiba Mika M   Takahashi Satoshi S   Nakamichi Shinji S   Matsumoto Masaru M   Takeuchi Susumu S   Minegishi Yuji Y   Noro Rintaro R   Kunugi Shinobu S   Kubota Kaoru K   Gemma Akihiko A  

Scientific reports 20181005 1

Overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is critical in combating EGFR-mutant non-small cell lung cancer (NSCLC). We tried to construct a novel therapeutic strategy to conquer the resistance to second-and third-generation EGFR-TKIs in EGFR-positive NSCLC patients. We established afatinib- and osimertinib-resistant lung adenocarcinoma cell lines. Exome sequencing, cDNA array and miRNA microarray were performed using the established  ...[more]

Similar Datasets

2017-01-01 | S-EPMC5642590 | BioStudies
1000-01-01 | S-EPMC6173712 | BioStudies
2017-01-01 | S-EPMC5536882 | BioStudies
2020-01-01 | S-EPMC7004431 | BioStudies
1000-01-01 | S-EPMC5834054 | BioStudies
2020-01-01 | S-EPMC7330330 | BioStudies
2017-01-01 | S-EPMC5571822 | BioStudies
1000-01-01 | S-EPMC4638008 | BioStudies
2019-01-01 | S-EPMC6486868 | BioStudies
2018-01-01 | S-EPMC5784552 | BioStudies